What is Rydapt used for?

Rydapt is used alongside certain chemotherapy treatments in adults who have been newly diagnosed with acute myeloid leukaemia, and have a change (mutation) in what is called the ‘FLT3’ gene. Your doctor will do a test to see if Rydapt is right for you. It is not known if Rydapt is safe and effective in children.

How Rydapt works

Rydapt works by blocking the signals from the FLT3 receptor that help certain cells grow and divide. Blocking these signals may help kill leukaemia cells in the blood and bone marrow. This is why Rydapt is only suitable for patients with a FLT3 mutation, and is known as a 'targeted therapy'.

Rydapt is used in combination with standard induction and consolidation chemotherapy treatment cycles.

More information

For more information about Rydapt please consult:

Summary of product characteristics (SmPC) for Rydapt
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

Patient information leaflet (PIL) for Rydapt
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

 

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See yellowcard.mhra.gov.uk for how to report side effects.

Reference

  1. Rydapt Summary of Product Characteristics. Novartis Pharma AG 2018.
ONC20-C056 June 2020.
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You should also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk.
By reporting side effects you can help provide more information on the safety of this medicine.